International Journal of Celiac Disease
ISSN (Print): 2334-3427 ISSN (Online): 2334-3486 Website: Editor-in-chief: Samasca Gabriel
Open Access
Journal Browser
International Journal of Celiac Disease. 2014, 2(1), 6-10
DOI: 10.12691/ijcd-2-1-3
Open AccessArticle

Sprue-like Intestinal Disease

Hugh James Freeman1,

1Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, Canada

Pub. Date: January 16, 2014

Cite this paper:
Hugh James Freeman. Sprue-like Intestinal Disease. International Journal of Celiac Disease. 2014; 2(1):6-10. doi: 10.12691/ijcd-2-1-3


Recurrent symptoms in well-established celiac disease may result in further clinical evaluation. In most, poor diet compliance is present. Other considerations include an unidentified gluten source, an erroneous initial diagnosis, another or second and superimposed cause for symptoms, or a complication, including collagenous sprue or an intestinal lymphoma. Failure to define an initial gluten-free diet response, however, suggests that celiac disease may not be present. Instead, a distinctive enteropathic process, refractory to diet restrictions, including gluten, is evident. This “sprue-like” intestinal disorder or enteropathy remains unclassified, and probably, represents a heterogeneous entity. Molecular changes suggestive of early clonal expansion of an aberrant population of intra-epithelial lymphocytes may be detected in some (with or without a prior gluten-free diet response), and these changes may signify an early or “cryptic’ lymphoma. Other newly recognized lymphoproliferative disorders occurring in the setting of celiac disease have been recorded, including hepatosplenic delta-gamma T-cell lymphoma, an indolent CD4+ T-cell lymphoma, particularly in younger males, and large granular lymphocytic leukemia, a possibly treatable disorder characterized by the clonal expansion of T-cells in blood and small intestinal mucosa. Studies using IL-15 blockade in a transgenic mouse model with pathologic features of a sprue-like intestinal disease has led to human clinical trials with encouraging positive results.

celiac disease refractory celiac disease sprue-like intestinal disease sprue-like enteropathy unclassified sprue gluten-sensitive enteropathy celiac sprue

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Freeman. HJ, Chopra A, Clandinin MT, Thomson AB. Recent advances in celiac disease. World J Gastroenterol 2011; 17: 2259-2272.
[2]  Gujral N, Freeman HJ, Thomson AB. Celiac disease: prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol 2012; 18: 6036-6059.
[3]  Freeman HJ. Pearls and pitfalls in the diagnosis of adult celiac disease. Can J Gastroenterol 2008; 22: 273-280.
[4]  MacDonald WC, Brandborg LL, Flick AL, Trier JS, Rubin CE. Studies of celiac sprue. IV. The response of the whole length of the small intestine to a gluten-free diet. Gastroenterology 1964; 47: 573-589.
[5]  Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Inchingolo CD, Monardo E, Aiello F. Endoscopic and histologic findings in the duodenum of adults with celiac disease before and after changing to a gluten-free diet: a 2-year prospective study. Endoscopy 2006; 38: 702-707.
[6]  Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the United States. Am J Gastroenterol 2012; 107: 1538-1544.
[7]  Freeman HJ. Detection of adult celiac disease using duodenal screening biopsies over a 30-year period. Can J Gastroenterol 2013; 27: 405-408.
[8]  Freeman HJ. Sulindac-associated small bowel lesion. J Clin Gastroenterol 1986; 8: 569-571.
[9]  Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012; 87: 732-738.
[10]  Gentile NM, D’Souza A, Fujii LL, Wu TT, Murray JA. Association between ipilimumab and celiac disease. Mayo Clin Proc 2013; 88: 414-417.
[11]  Faulkner-Hogg KB, Selby WS, Loblay RH. Dietary analysis in symptomatic patients with coeliac disease on a gluten-free diet: the role of trace amounts of gluten and non-gluten food intolerances. Scand J Gastroenterol 1999; 34: 784-789.
[12]  Hollon JR, Cureton PA, Martin ML, Puppa EL, Fasano A. Trace gluten contamination may play a role in mucosal and clinical recovery in a subgroup of diet-adherent non-responsive celiac disease patients. BMC Gastroenterol 2013; 13: 40.
[13]  Schuffler MD, Chaffee RG. Small intestinal biopsy in a patient with Crohn’s disease of the duodenum. The spectrum of abnormal findings in the absence of granulomas. Gastroenterology 1979; 76: 1009-1014.
[14]  Freeman HJ. Collagenous colitis as the presenting manifestation of biopsy-defined celiac disease. J Clin Gastroenterol 2004; 38: 664-668.
[15]  Rubin CE, Eidelman S, Weinstein WM. Sprue by any other name. Gastroenterology 1970; 58: 409-413.
[16]  Freeman HJ. Adult autoimmune enteropathy. World J Gastroenterol 2008; 14: 1156-1158.
[17]  Malamut G, Verkarre V, Callens C, Colussi O, Rahmi G, MacIntyre E, Haioun C, Meresse B, Brousse N, Romana S, Hermine O, Cerf-Bensussan N, Cellier C. Enteropathy-associated T-cell lymphoma complicating an autoimmune enteropathy. Gastroenterology 2012; 142: 726-729.
[18]  Malamut G, Meresse B, Kaltenbach S, Derrieux C, Verkarre V, Macintyre E, Ruskone-Fourmestraux A, Fabiani B, Radford-Weiss I, Brousse N, Hermine O, Cerf-Bensussan N, Cellier C. Small intestinal CD4+ T-cell lymphoma is a heterogeneous entity with common pathology features. Clin Gastroenterol Hepatol 2013; in press.
[19]  Harris OD, Cooke WT, Thompson H, Waterhouse JA. Malignancy in adult celiac disease and idiopathic steatorrhea. Am J Med 1967; 42: 899-912.
[20]  Freeman HJ, Weinstein WM, Shnitka TK, Piercey JR, Wensel RH. Primary abdominal lymphoma. Presenting manifestation of celiac sprue or complicating dermatitis herpetiformis. Am J Med 1977; 63: 585-594.
[21]  Freeman HJ, Chiu BK. Multifocal small bowel lymphoma and latent celiac sprue. Gastroenterology 1986; 90: 1992-1997.
[22]  Cellier C, Patey N, Mauvieux L, Jabri B, Delabesse E, Cervoni JP, Burtin ML, Guy-Grand D, Bouhnik Y, Modigliani R, Barbier JP, Macintyre E, Brousse N, Cerf-Bensussan N. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 1998; 114: 471-481.
[23]  Malamut G, Afchain P, Verkarre V, Lecomte T, Amiot A, Damotte D, Bouhnik Y, Colombel JF, Delchier JC, Allez M, Cosnes J, Lavergne-Slove A, Meresse B, Trinquart L, Macintyre E, Radford-Weiss I, Hermine O, Brousse N, Cerf-Bensussan N, Cellier C. Presentation and long-term follow-up of refractory celiac disease: comparison of type 1 with type II. Gastroenterology 2009; 136: 81-90.
[24]  Freeman HJ. Free perforation due to intestinal lymphoma in biopsy-defined or suspected celiac disease. J Clin Gastroenterol 2003; 37: 299-302.
[25]  Daum S, Weiss D, Hummel M, Ullrich R, Heise W, Stein H, Riecken EO, Foss HD; Intestinal Lymphoma Study Group. Frequency of clonal intra-epithelial T-lymphocyte proliferations in enteropathy-type intestinal T-cell lymphoma, celiac disease, and refractory sprue. Gut 2001; 49: 804-812.
[26]  Freeman HJ. Lymphoproliferative and intestinal malignancies in 214 patients with biopsy-defined celiac disease. J Clin Gastroenterol 2004; 38: 429-434.
[27]  Freeman HJ. Adult celiac disease and its malignant complications. Gut Liver 2009; 3: 237-246.
[28]  Smedby KE, Akerman M, Hildebrand H, Glimelius B, Ekbom A, Askling J. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut 2005; 54: 54-59.
[29]  Yuan CM, Stein S, Glick JH, Wasik MA. Natural killer-like T-cell lymphoma of the small intestine with a distinct immunophenotype and lack of association with gluten-sensitive enteropathy. Arch Pathol Lab Med 2003; 127: e142-e146.
[30]  Muram-Zborovski T, Loeb D, Sun T. Primary intestinal intraepithelial natural killer-like T-cell lymphoma: a case report of a distinct clinicopathological entity. Arch Pathol Lab Med 2009; 133: 133-137.
[31]  Freeman HJ. Fulminant liver failure with necrotizing foci in the liver, spleen and lymph nodes in celiac disease due to malignant lymphoma. Can J Gastroenterol 1996; 10: 225-229.
[32]  Freeman HJ. T-cell lymphoma of the thyroid gland in celiac disease. Can J Gastroenterol 2000; 14: 635-636.
[33]  Carbonnel F, D’Almagne H, Lavergne A, Matuchansky C, Brouet JC, Sigaux F, Beaugerie L, Nemeth J, Coffin B, Cosnes J, Gendre JP, Rambaud JC. The clinicopathological features of an extensive small intestinal CD4 T-cell infiltration. Gut 1999; 45: 662-667.
[34]  Zivny J, Banner BF, Agrawal S, Pihan G, Barnard GF. CD4+ T-cell lymphoproliferative disorder of the gut clinically mimicking celiac sprue. Dig Dis Sci 2004; 48: 551-555.
[35]  Svrcek M, Garderet I, Sebbagh V, Rosenzwajg M, Parc Y, Lagrange M, Bennis M, Lavergne-Slove A, Flejou JF, Fabiani B. Small intestinal CD4+ T-cell lymphoma: a rare distinctive clinicopathological entity associated with prolonged survival. Virchows Arch 2007; 451: 1091-1093.
[36]  Margolskee E, Jobanputra V, Lewis SK, Alobeid B, Green PH, Bhagat G. Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features. PLoS One 2013; 8: e68343.
[37]  Lopez P, Morris DG, Galbraith PR, Lillicarp DP, Pross HF. Lymphoproliferative disease of “LAK cell” precursor large granular lymphocytes in association with celiac disease. Am J Hematol 1993; 43: 116-122.
[38]  Molitor JL, Saint-Louis J, Louvet C, Vachon A, Vincent L, Beaulieu R. Large granular T-cell lymphocytic leukemia disclosed by bilateral uveitis: association with celiac disease. Rev Med Interne 1997; 18: 237-239.
[39]  Malamut G, Meresse B, Verkarre V, Kaltenbach S, Montcuquet N, Duong Van Huyen J-P, Callens C, Lenglet J, Rahmi G, Samaha E, Ranque B, Macintyre E, Radford-Weiss I, Hermine O, Cerf-Bensussan N, Cellier C. Large granular lymphocytic leukemia: a treatable form of refractory celiac disease. Gastroenterology 2012; 143: 1470-1472.
[40]  Yokoyama S, Watanabe N, Sato N, Perera PY, Filkoski L, Tanaka T, Miyasaka M, Waldman TA, Hiroi T, Perera LP. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci USA 2009; 106: 15849-15854.
[41]  Yokoyama S, Perera PY, Waldmann TA, Hiroi T, Perera LP. Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. J Clin Immunol 2013; 33: 586-594.
[42]  Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC. Phase 1 trial of IL-15 trans presentation blockade using humanized MikB1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood 2013; 121: 476-484.
[43]  Brar P, Lee S, Lewis S, Egbuna I, Bhagat G, Green PH. Budesonide in the treatment of refractory celiac disease. Am J Gastroenterol 2007; 102: 2265-2269.
[44]  Goerres MS, Meijer JW, Wahab PJ, Kerckhaert JA, Groenen PJ, van Krieken JH, Mulder CJ. Azathioprine and prednisone combination therapy in refractory coeliac disease. Alim Pharm Ther 2003; 18: 487-494.
[45]  Tack GJ, van Asseldonk DP, van Wanrooij RL, van Bodegraven AA, Mulder CJ. Tioguanine in the treatment of refractory coeliac disease—a single center experience. Aliment Pharm Ther 2012; 36: 274-281.
[46]  Gillett HR, Arnott ID, McIntyre M, Campbell S, Dahele A, Priest M, Jackson R, Ghosh S. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 2002; 122: 800-805.
[47]  Constantino G, della Torre A, Lo Presti MA, Caruso R, Mazzon E, Fries W. Treatment of life-threatening type 1 refractory coeliac disease with long-term infliximab. Dig Liver Dis 2008; 40: 74-77.
[48]  Vivas S, Ruiz de Morales JM, Ramos F, Suarez-Vilela D. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med 2006; 354: 2514-2515.
[49]  Tack GJ, Verbeek WH, Al-Toma A, Kuik DJ, Schreurs MW, Visser O, Mulder CJ. Evaluation of cladribine treatment in refractory celiac disease type II. World J Gastroenterol 2011;17: 506-513.
[50]  Al-Toma A, Goerres MS, Meijer JW. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol 2006; 4: 1322-1327.
[51]  Tack GJ, Wondergem MJ, Al-Toma A, Verbeek WH, Schmittel A, Machado MV, Perri F, Ossenkoppele GJ, Huijgens PC, Schreurs MW, Mulder CJ, Visser OJ. Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy. Bone Marrow Transplant 2011; 46: 840-846.
[52]  Al-Toma A, Visser OJ, van Roessel HM, von Blomberg BM, Verbeek WH, Scholten PE, Ossenkoppele GJ, Huijgens PC, Mulder CJ. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007; 109: 2243-2249.
[53]  Tack GJ, van Wanrooij RL, Von Blomberg BM, Amini H, Coupe VM, Bonnet P, Mulder CJ, Schreurs MW. Serum parameters in the spectrum of celiac disease: beyond standard antibody testing-a cohort study. BMC Gastroenterol 2012; 12: 159.
[54]  De Nitto D, Monteleone I, Franze E, Pallone F, Monteleone G. Involvement of interleukin-15 and interleukin-21, two gamma-chain-related cytokines, in celiac disease. World J Gastroenterol 2009; 15: 4609-4614.
[55]  Malamut G, El Machhour R, Montcuquet N, Martin-Lanneree S, Dusanter-Fourt I, Verkarre V, Mention JJ, Rahmi G, Kiyone H, Butz EA, Brousse N, Cellier C, Cerf-Bensussan N, Meresse B. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest 2010; 120: 2131-2143.
[56]  Schmitz F, Tjon JM, Lai Y, Thompson A, Kooy-Winkelaar Y, Lemmers RJ, Verspaget HW, Mearin ML, Staal FJ, Schreurs MW, Cupedo T, Langerak AW, Mulder CJ, van Bergen J, Koning F. Identification of a potential physiological precursor of aberrant cells in refractory coeliac disease type II. Gut 2013; 62: 509-519.
[57]  Zevallos VF, Schuppan D. Refractory celiac disease: one step closer to the origin of aberrant lymphocytes. Gut 2013; 62: 485-486.